Supplementary Table 1.docx (17.64 kB)
Supplementary Table 1: Impact of ALK fusion variant on clinical outcomes in EML4-ALK NSCLC patients: a systematic review and meta-analysis
datasetposted on 2021-11-16, 15:53 authored by Shasha Wang, Rongrong Luo, Yuankai Shi, Xiaohong Han
Supplementary Table 1: Impact of ALK Fusion Variant on Clinical Outcomes in EML4-ALK NSCLC Patients: a systematic review and meta-analysis.
Quality assessment of eligible studies using the Newcastle Ottawa quality assessment scale
Background: Emerging studies showed that ALK-fusion variants were associated with heterogeneous clinical outcomes. However, contradicting conclusions drew in some other studies considered no correlation between ALK variants and prognoses. Methods: we performed a systematic review and meta-analysis to evaluated the prognostic value of EML4-ALK fusion variants for the outcome of patients. Results: 28 studies were included in our analysis. According to the pooled results, patients harboring variant 1 showed equivalent PFS and OS with non-v1 (HR for PFS: 0.91(0.68-1.21), p=0.499; for OS: 1.12(0.73-1.72), p=0.610). Similarly, patients with v3 showed the same disease progress with non-v3 (pooled HR for PFS=1.07(0.72-1.58), p=0.741). However, pooled results for OS suggested that patients with v3 had a worse survival than non-v3 (HR=3.44(1.42-8.35), p=0.006). Conclusion: Overall results suggested that patients with v1 exhibited no significant difference with non-v1 in terms of OS and PFS, while v3 was associated with shorter OS in ALK-positive NSCLC patients.